To assess radiographic progression , physical function , clinical disease activity , and safety in patients with rheumatoid arthritis ( RA ) who had inadequate response to methotrexate ( MTX ) and who were treated with tocilizumab-MTX or MTX during Year 2 of a 2-year study .
